Login to Your Account

Crownbio spin-off to develop China-discovered oncology assets in U.S.

By Shannon Ellis
Staff Writer

Monday, August 29, 2016

SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription